News
Perion Network to Announce Fourth Quarter and Annual 2021 Financial Results on February 9, 2022
Perion Network Ltd. (NASDAQ:PERI) a global advertising technology company that delivers holistic solutions across the three main pillars of digital advertising – ad search, social media and display
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and
Agilent Presents Thought Leader Award to Professor Jason Kovacic
Agilent Technologies Inc. (NYSE: A) today announced that Professor Jason Kovacic has been selected to receive a prestigious Agilent Thought Leader Award. Professor Kovacic is being recognized for
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial
DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2021.* Novocure is a global oncology company
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate
Puma Biotechnology Releases Updated Corporate Presentation
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, presented at
STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary results for the
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced they
Investor and Analyst Event: Exelon Details Strategy for Nation’s Largest Fully Regulated Utility Company
Exelon Corp. (Nasdaq: EXC) will host an investor and analyst event today, January 10, beginning at 12:00 p.m. Central Time, 1:00 p.m. Eastern Time. Exelon management will outline how the company is
DGAP-News: GEA Group Aktiengesellschaft: A capital market information
Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.
Owens & Minor, Inc. (“Owens & Minor”) (NYSE: OMI) and Apria, Inc. (“Apria”) (Nasdaq: APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year
DGAP-News: H&R GmbH & Co. KGaA: Joint Venture P2X Europe and Nordic Electrofuel cooperate on PtL products
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
DGAP-News: INDUS Holding AG: INDUS places second ESG-linked promissory note loan
Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the closing of its previously announced acquisition of Ivantis®, developer of the
EQS-News: Nordea Bank Abp: Transaction in Own Shares
DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
DGAP-News: Successful year-end sprint 2021 - total transaction volume of DIC up to c. EUR 1.9 billion